Last reviewed · How we verify
NCT03304990
Panomics Relationships in the Epidemiology of Cancer Through In Silico Expression (PRECISE)
trial testing Patients with CA or suspected risk of CA or a family Hx in Cancer. Withdrawn.
1 January 2019
Quick facts
| Lead sponsor | Greater Baltimore Medical Center |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 29 November 2018 |
| Primary completion | 1 January 2019 |
| Estimated completion | 1 January 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Patients with CA or suspected risk of CA or a family Hx
Conditions studied
- Cancer — all drugs for Cancer →
- Patients With Clinical and Environmental Risk Factors for Cancer — all drugs for Patients With Clinical and Environmental Risk Factors for Cancer →
- Patients With a Suspected or Confirmed Diagnosis of Cancer — all drugs for Patients With a Suspected or Confirmed Diagnosis of Cancer →
Sponsor
Greater Baltimore Medical Center
Who can join
18 and older, any sex, with Cancer or Patients With Clinical and Environmental Risk Factors for Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
PRECISE is a study to discover new detection, prognosis and treatment biomarkers for cancer. This is a prospective, multi-center, observational study designed to collect de-identified biospecimens and clinical data from a large cohort of participants from clinical research networks in the United States. In this study, the investigators propose creating a large-scale normalized panomics dataset specifically designed for deep learning-based in silico analysis for biomarker discovery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03304990
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Greater Baltimore Medical Center trials
Trials by the same sponsor.
- NCT03285802 — Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutat · Phase 2, PHASE3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03304990 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Greater Baltimore Medical Center
- Last refreshed: 22 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03304990.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing